Brian Abrahams is ranked #1905 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Brian Abrahams

RBC

Brian Abrahams

Q: How accurate are Brian Abrahams's stock ratings?

About 51% of Brian's ratings were profitable over a one-year hold, with an average return of -0.0% per rating, measured by 13Foresight from historical prices.

RBC Capital

Wall Street Analyst

★★★☆☆

#1905

on 13Foresight · ranked by our own returns

51%

Success Rate

-0.1%

Average Return

88 of 173 calls profitable · -126.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 51% of Brian Abrahams's ratings turned a profit when each position was held for 1 year — averaging -0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

149 Buy 124 Hold 5 Sell

Brian's Stock Coverage 63 ratings · 2026-11-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
KYMR Kymera Therapeutics	Oct 29, 2026	HOLD	Strong Buy -9.6% avg upside 39 analysts	$116.00 8.37% Downside	+4.0%	·
PTCT PTC Therapeutics	Oct 29, 2026	HOLD	Buy +35.4% avg upside 29 analysts	$77.00 28.44% Upside	-1.5%	·
INCY Incyte	Oct 29, 2026	HOLD	Buy -5.9% avg upside 49 analysts	$117.00 2.77% Downside	+4.2%	·
GILD Gilead Sciences	Oct 29, 2026	HOLD	Strong Buy -27.3% avg upside 66 analysts	$131.00 23.28% Downside	+1.5%	·
BIIB Biogen	Oct 28, 2026	BUY	Strong Buy +6.6% avg upside 53 analysts	$272.00 7.34% Upside	+3.8%	·
SRPT Sarepta Therapeutics	Oct 27, 2026	HOLD	Buy +223.8% avg upside 50 analysts	$17.00 8.73% Downside	-15.1%	·
MLTX MoonLake Immunotherapeutics	Oct 27, 2026	HOLD	Strong Buy +158.9% avg upside 20 analysts	$17.00 44.30% Upside	+4.8%	·
KPTI Karyopharm Therapeutics	Oct 27, 2026	BUY	Strong Buy +2682.1% avg upside 18 analysts	$8.00 1108.47% Upside	-89.6%	·
REGN Regeneron	Oct 27, 2026	HOLD	Strong Buy -12.1% avg upside 60 analysts	$810.00 12.67% Downside	+17.1%	·
AARD Aardvark Therapeutics, Inc.	Oct 23, 2026	HOLD	Buy +1101.0% avg upside 12 analysts	$2.50 83.85% Upside	-4.3%	·
DFTX Definium Therapeutics	Oct 19, 2026	BUY	Strong Buy +48.7% avg upside 24 analysts	$66.00 81.76% Upside	-2.7%	·
NBIX Neurocrine	Oct 13, 2026	BUY	Strong Buy +27.3% avg upside 37 analysts	$187.00 27.91% Upside	+25.4%	·
NRIX Nurix Therapeutics	Oct 12, 2026	BUY	Strong Buy +22.5% avg upside 28 analysts	$35.00 30.59% Upside	-30.1%	·
BCRX BioCryst	Oct 08, 2026	HOLD	Strong Buy +113.8% avg upside 24 analysts	$11.00 29.93% Upside	-8.0%	·
VRTX Vertex Pharmaceuticals	Oct 08, 2026	BUY	Strong Buy -20.5% avg upside 62 analysts	$576.00 3.02% Upside	+8.9%	·
ACAD ACADIA Pharmaceuticals	Oct 08, 2026	BUY	Strong Buy +71.5% avg upside 43 analysts	$36.00 74.82% Upside	-4.2%	·
XENE Xenon	Oct 01, 2026	BUY	Strong Buy +53.0% avg upside 28 analysts	$70.00 87.13% Upside	+4.0%	·
LKFT Lakefront Biotherapeutics	Sep 23, 2026	BUY	Buy +217.3% avg upside 25 analysts	$45.00 39.42% Upside	+8.9%	·
CTNM Contineum Therapeutics, Inc. Class A	Sep 21, 2026	BUY	Strong Buy +126.3% avg upside 9 analysts	$21.00 123.64% Upside	-27.2%	·
EVMN Evommune, Inc.	Sep 08, 2026	BUY	Strong Buy +283.4% avg upside 13 analysts	$21.00 212.14% Upside	-41.7%	·
ATTO Attovia Therapeutics, Inc.	Sep 02, 2026	BUY	Strong Buy +161.7% avg upside 4 analysts	$45.00 196.28% Upside	-35.1%	·
NMRA Neumora Therapeutics, Inc.	Aug 14, 2026	BUY	Strong Buy +1957.6% avg upside 11 analysts	$5.00 1261.67% Upside	-73.1%	·
CRBP Corbus Pharmaceuticals	Aug 12, 2026	BUY	Strong Buy +713.3% avg upside 20 analysts	$36.00 753.07% Upside	-65.3%	·
PLRX Pliant Therapeutics	Aug 11, 2026	HOLD	Buy +2494.5% avg upside 21 analysts	$2.00 132.78% Upside	-32.0%	·
DMRA Damora Therapeutics	Aug 10, 2026	BUY	Strong Buy +39.9% avg upside 20 analysts	$40.00 86.17% Upside	-19.8%	·
SION Sionna Therapeutics, Inc.	Aug 10, 2026	HOLD	Buy +461.5% avg upside 12 analysts	$5.00 29.13% Upside	-24.2%	·
ATYR aTyr Pharma	Aug 09, 2026	HOLD	Buy +69.8% avg upside 17 analysts	$1.00 79.70% Downside	·	·
GHRS GH Research	Aug 06, 2026	BUY	Strong Buy +90.1% avg upside 12 analysts	$42.00 101.40% Upside	-36.2%	·
PRTA Prothena	Aug 06, 2026	HOLD	Buy +195.2% avg upside 14 analysts	$13.00 53.56% Upside	-4.9%	·
MIRM Mirum Pharmaceuticals	Apr 07, 2026	BUY	Strong Buy +48.1% avg upside 24 analysts	$128.00 50.64% Upside	-1.7%	·
TSE:SOBO South Bow Corp	Oct 26, 2025	BUY	Hold -6.7% avg upside 20 analysts	$39.00 22.43% Downside	+45.6%	·
ENTA Enanta Pharmaceuticals	Oct 02, 2023	HOLD	Buy +206.4% avg upside 17 analysts	$15.00 40.02% Upside	+7.2%	·
VERX Vertex	Oct 28, 2022	HOLD	Buy +117.1% avg upside 24 analysts	$288.00 1779.97% Upside	+27.8%	·
OVID Ovid Therapeutics	Aug 16, 2021	HOLD	Strong Buy +103.8% avg upside 19 analysts	$4.00 57.53% Upside	-41.2%	·
AMGN Amgen	Oct 26, 2017	HOLD	Buy -29.9% avg upside 57 analysts	$188.00 59.64% Downside	+8.4%	·
ABEO Abeona Therapeutics	Sep 15, 2017	BUY	Strong Buy +295.1% avg upside 18 analysts	$23.00 428.71% Upside	·	·
CVX Chevron	May 17, 2017	BUY	Strong Buy -16.9% avg upside 44 analysts	$135.00 42.64% Downside	+28.4%	·
RARE Ultragenyx Pharmaceutical	May 08, 2017	HOLD	Strong Buy +193.8% avg upside 36 analysts	$68.00 322.33% Upside	-3.8%	·
OSK Oshkosh	Apr 27, 2017	BUY	Strong Buy +0.5% avg upside 28 analysts	$80.00 42.89% Downside	+3.1%	·
FE FirstEnergy	Mar 31, 2017	HOLD	Buy +3.2% avg upside 27 analysts	$32.00 31.79% Downside	+11.9%	·
ARCT Arcturus Therapeutics	Mar 31, 2017	HOLD	Buy +175.7% avg upside 36 analysts	$8.75 20.57% Downside	-31.1%	·
PEG Public Service Enterprise	Mar 31, 2017	HOLD	Buy +9.3% avg upside 33 analysts	$46.50 37.49% Downside	+17.5%	·
QURE uniQure	Mar 07, 2017	HOLD	Strong Buy +121.1% avg upside 30 analysts	$8.00 67.84% Downside	+345.4%	·
AFMDQ Affimed	Feb 16, 2017	HOLD	Buy +1359021112.1% avg upside 16 analysts	$2.50 249999899.96% Upside	·	·
DBVT DBV Technologies SA - American	Feb 09, 2017	BUY	Buy +143.7% avg upside 15 analysts	$47.00 395.26% Upside	-36.6%	·
HAE Haemonetics	Jan 05, 2017	BUY	Buy -20.9% avg upside 18 analysts	$42.00 64.81% Downside	+59.1%	·
CLDX Celldex	Nov 23, 2016	HOLD	Strong Buy +42.9% avg upside 28 analysts	$5.00 83.35% Downside	-34.0%	·
RRC Range Resources	Nov 16, 2016	BUY	Buy -28.7% avg upside 43 analysts	$46.00 15.70% Downside	-49.8%	·
CMCSA Comcast	Nov 16, 2016	BUY	Buy +61.5% avg upside 42 analysts	$38.50 65.82% Upside	+11.7%	·
CVS CVS Health	Nov 01, 2016	BUY	Strong Buy +19.5% avg upside 39 analysts	$122.00 35.27% Upside	-15.2%	·
BMRN BioMarin Pharmaceutical	Sep 07, 2016	BUY	Strong Buy +63.6% avg upside 52 analysts	$120.00 105.18% Upside	-5.9%	·
ABBV AbbVie	Aug 25, 2016	BUY	Strong Buy -14.5% avg upside 47 analysts	—	+12.0%	·
BMY Bristol-Myers Squibb	Aug 22, 2016	HOLD	Buy -2.2% avg upside 42 analysts	—	+0.1%	·
AGEN Agenus	Aug 08, 2016	BUY	Strong Buy +72.3% avg upside 19 analysts	—	·	·
LLY Eli Lilly & Co	Aug 08, 2016	BUY	Strong Buy -16.7% avg upside 50 analysts	—	+3.1%	·
JNJ Johnson & Johnson	Aug 01, 2016	HOLD	Strong Buy -9.1% avg upside 40 analysts	—	+8.5%	·
PFE Pfizer	Jul 15, 2016	BUY	Buy +9.2% avg upside 46 analysts	—	-5.6%	·
CLLS Cellectis SA	Jul 15, 2016	BUY	Buy +1837.3% avg upside 16 analysts	—	+8.1%	·
MRK Merck & Company	Jul 15, 2016	HOLD	Strong Buy -3.5% avg upside 44 analysts	—	+8.9%	·
NVS Novartis	Apr 21, 2016	BUY	Hold -16.1% avg upside 24 analysts	$60.50 62.40% Downside	-0.3%	·
RIGL Rigel	Feb 23, 2015	HOLD	Buy -47.4% avg upside 17 analysts	—	-28.2%	·
PLX Protalix	Jun 25, 2012	HOLD	Buy +221.7% avg upside 4 analysts	—	·	·
NVAX Novavax	Sep 02, 2009	HOLD	Buy +130.1% avg upside 20 analysts	—	-60.9%	·

🔒 58 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brian Abrahams — Frequently Asked Questions

How accurate are Brian Abrahams's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Brian's ratings were profitable over a one-year hold, with an average return of -0.0% per rating, or -126.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Brian ranked on 13Foresight?

Brian Abrahams is currently ranked #1905 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brian cover?

Brian most recently has ratings on KYMR, PTCT, INCY, GILD, BIIB, SRPT, MLTX, KPTI, REGN, AARD, DFTX, NBIX and 51 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Brian Abrahams

Rating Distribution

Welcome to 13Foresight!